Medicinova Inc
MNOV Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.39
KIRA · Stoqly’s AI analyst, in plain words
- Medicinova Inc had $0.4M of revenue in fiscal 2025.
- Its operating margin was −3,242.1%: of every 100 in sales, about −3,242 is left after running the business.
- Medicinova Inc lost $12.0M in fiscal 2025.
- Free cash flow was −$9.8M in fiscal 2025, −2,395.2% of revenue.
Market cap
$68.4M
P/E
—
Revenue
$0.4M
Net income
−$12.0M
Free cash flow
−$9.8M
Operating margin
−3,242.1%
Medicinova Inc in 30 seconds · fiscal 2025
Does it make a profit?
−2,928.5%
No. It lost money last year.
Does profit turn into cash?
−2,395.2%
No. It spent more cash than it brought in.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Medicinova Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- MEDICINOVA INC
- CIK
- 0001226616
Medicinova Inc · MNOV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.0M | — | $1.0M | — | $0.4M |
| Operating margin | −253.0% | — | −990.0% | — | −3,242.1% |
| Net income | −$10.1M | −$14.1M | −$8.6M | −$11.0M | −$12.0M |
| Net margin | −251.0% | — | −857.2% | — | −2,928.5% |
| Diluted EPS | −$0.21 | −$0.29 | −$0.17 | −$0.23 | −$0.24 |
| Cash | |||||
| Cash from operations | −$9.4M | −$12.9M | −$7.4M | −$10.6M | −$9.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$9.4M | −$12.9M | −$7.5M | −$10.6M | −$9.8M |
| FCF margin | −233.1% | — | −745.2% | — | −2,395.2% |
| Share count change | 9.4% | 0.9% | 0.0% | 0.0% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $71.4M | $58.5M | $51.0M | $40.4M | $30.8M |
| Shareholders' equity | $83.7M | $70.2M | $62.4M | $52.5M | $41.6M |
| Current ratio | 25.4x | 18.5x | 15.6x | 13.9x | 8.2x |
| Returns and quality | |||||
| Return on equity | −13.1% | −18.3% | −12.9% | −19.2% | −25.5% |
| Return on tangible equity | −13.7% | −23.2% | −16.2% | −25.8% | −37.5% |
| Altman Z'' | 13.3 | 4.6 | 0.1 | −5.6 | −18.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.7M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Medicinova Inc · MNOV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.39 a share, the company is worth $68.4M.
Source: SEC EDGAR XBRL filings (CIK 0001226616). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.